Durata Therapeutics Inc. clinical trials
Acquired by AbbVie, May 8, 2020 · source ↗
The registry lists 6 studies whose lead sponsor is Durata Therapeutics Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 4, 2019.
Before and after it joined AbbVie
- First submitted before Durata Therapeutics Inc. became part of AbbVie
- 6
- First submitted after Durata Therapeutics Inc. became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 5
- Withdrawn
- 1
Registry sponsor names on this page
- Durata Therapeutics Inc., an affiliate of Allergan plc6 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All AbbVie studies →
- Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With OsteomyelitisCompletedNCT02685033Phase 2
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie
- Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT02127970Phase 3
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie
- A P3 Comparator Trial in Community Acquired Bacterial PneumoniaWithdrawnNCT02269644Phase 3
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie
- A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.CompletedNCT01946568Phase 1
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie
- Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01431339Phase 3
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie
- Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01339091Phase 3
Sponsor listed in the registry: Durata Therapeutics Inc., an affiliate of Allergan plc · First submitted before Durata Therapeutics Inc. became part of AbbVie